VivoSim Labs
- Company typePublic
- Founded2007
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
VivoSim Labs firmographics
Firmographics- Name
- VivoSim Labs
- Legal name
- VivoSim Labs, Inc.
- Website
- https://vivosim.ai
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
VivoSim Labs industry classification
Industry- Product category
- Preclinical Toxicology Testing Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)
- akta.pro primary industry
- In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ)
Keywords
Where VivoSim Labs is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
VivoSim Labs business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Toxicology Testing Services: VivoSim Labs generates revenue through contracted toxicology testing services using NAMkind™ 3D liver and intestine models. Services include prospective screens (20+ compounds in 2 weeks), translational bridge studies, and investigative toxicology (1-2 compounds across multiple concentrations with 4-week turnaround). Standard liver service screens 36-40 compounds at 4 concentrations each with 17-day treatment period; GI service tests 30 compounds with 7-day exposure protocol.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Prospective Toxicity Screens |
| Other | Multi-year contract | Translational Risk Bridge |
| Other | Multi-year contract | Investigative Toxicology |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
VivoSim Labs product offering
Product offeringCore offering
VivoSim Labs develops NAMkind™ 3D human liver and intestinal tissue models built from primary human cells (hepatocytes, Kupffer cells, endothelial and stellate cells for liver; epithelial and stromal cells for intestine) and delivers contracted toxicology testing services using these models. The offerings include prospective compound screens, translational bridge studies with species-specific variants, and on-demand investigative toxicology, all aligned with FDA's New Approach Methodology (NAM) framework to provide human-relevant safety data for pharmaceutical and biotech drug development pipelines.
Product overview
VivoSim Labs offers a unified portfolio of NAMkind™ 3D human tissue models and associated toxicology testing services. The core products include the NAMkind™ Liver Model (3D liver spheroids with hepatocytes, Kupffer cells, endothelial, and stellate cells) and the NAMkind™ Intestine Model (3D Transwell platform with epithelial and stromal cells). These models are offered alongside three service tiers: Liver Toxicology Services (standard screening of up to 40 compounds over 17 days), Gastrointestinal Toxicology Services (intestinal barrier assessment over 7 days with TEER and viability readouts), and Investigative Toxicology Services (mechanistic studies for at-risk compounds in 4 weeks). All offerings are aligned with FDA's New Approach Methodology (NAM) framework and leverage primary human cells to provide human-relevant safety data for drug development.
Differentiator
Problem solved
Functional benefit
Brands
- NAMkind: 3D human tissue models including liver and intestine models for toxicology testing and drug development.
Products and services
- Liver Toxicology Services Contracted toxicology testing service using the NAMkind™ Liver Model that screens up to 40 compounds at multiple concentrations over a 17-day treatment period, measuring viability, functional output, and DILI biomarkers (LDH release, albumin secretion, ATP viability, glutathione status). Includes optional mechanistic panels and species-specific variants (rat, mouse, dog, monkey). Designed for pharmaceutical and biotech teams during Hit-to-Lead, Lead Optimization, and Candidate Nomination.
- Gastrointestinal Toxicology Services Full-service intestinal toxicity testing using the NAMkind™ Intestine Model. Tests up to 30 compounds over a 7-day exposure protocol at four concentrations, assessing barrier function (TEER), cell viability (ATP, Alamar Blue), and histological changes with a 4-week turnaround. Targets pharmaceutical and biotech programs with high GI toxicity risk such as oncology and IBD.
- Investigative Toxicology Services On-demand mechanistic toxicology service using BioPrint 3D human tissue models to investigate unexpected compound-related toxicity signals. Supports 1-2 compounds across multiple concentrations with a 4-week turnaround, providing insights into cellular stress, tissue damage, and inflammatory signaling to support go/modify/stop decisions.
Companies that use VivoSim Labs
Customer profileSegments3 records
Ideal customer profiles3 records
VivoSim Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
VivoSim Labs partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered regional.
- JCBioregionalKorean distribution partner for VivoSim products. Ensures hassle-free buying experience for customers in Korea. Listed on distributors page of VivoSim website alongside Tekon.
- TekonregionalChinese distribution partner (Tekon Biotech) for VivoSim products. Enables local access for customers in China. Listed alongside JCBio as regional distribution partners.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
VivoSim Labs competitors and assessment
Company assessmentEmerging players
- Emulate: Commercial-stage organ-on-chip company with Liver-Chip and Intestine-Chip products used by major pharma for preclinical safety assessment. Comparable to VivoSim's NAMkind portfolio in tissue types and target customers, though with a more capital-intensive chip platform.
- TissUse: Developer of multi-organ-chip microphysiological systems for toxicology and efficacy testing. Comparable to VivoSim as a NAM-focused tissue model company serving pharma R&D.
Broad incumbents
- Labcorp Drug Development (formerly Covance): Global CRO with a large preclinical toxicology practice, including emerging NAM offerings. Represents an incumbent competitor and potential partner for VivoSim's NAMkind services.
- Inotiv: Preclinical CRO offering toxicology, safety pharmacology, and research models. Comparable as an established alternative to VivoSim for outsourced preclinical toxicology studies.
- BioIVT: Supplier of primary human cells and in vitro test systems, including hepatocytes used in liver toxicology workflows. Comparable to VivoSim as a supplier into the human-relevant in vitro toxicology market, with potential partnership and overlap.
- Charles River Laboratories: Large preclinical CRO with extensive in vivo and in vitro toxicology service lines serving global pharma. Competes with VivoSim for preclinical safety spend and represents both a competitive threat and a potential partnership/buyer.
Direct peers
- MIMETAS: Offers OrganoPlate-based 3D tissue models and organ-on-chip toxicology screening services for pharmaceutical customers. Comparable to VivoSim on the technology axis (microfluidic 3D human tissue models) and the services business model.
- InSphero: Provider of 3D in vitro microtissue organoid models (liver, pancreas, etc.) for predictive toxicology and disease modeling. Closely comparable to VivoSim's NAMkind Liver platform in terms of primary-cell-based 3D spheroid technology and target customer base.
- Cyprotex (an Evotec company): Leading contract research organization specializing in in vitro and in silico ADME-Tox services, including liver and intestinal toxicity assays. Directly comparable to VivoSim as a commercial in vitro toxicology services provider for pharma and biotech.
- CN Bio: Developer of organ-on-chip and microphysiological systems, including liver and gut models for drug safety and efficacy testing. Direct peer to VivoSim in the NAM-based 3D tissue model space serving pharma preclinical safety applications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
VivoSim Labs social profiles
Digital presenceVivoSim Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
VivoSim Labs leadership team
Management profileNumber of profiles
Profiles4 records
VivoSim Labs funding detail
Funding detailFunding overview
Funding rounds9 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VivoSim Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VivoSim Labs
What does VivoSim Labs do?
VivoSim Labs develops NAMkind™ 3D human liver and intestinal tissue models built from primary human cells (hepatocytes, Kupffer cells, endothelial and stellate cells for liver; epithelial and stromal cells for intestine) and delivers contracted toxicology testing services using these models. The offerings include prospective compound screens, translational bridge studies with species-specific variants, and on-demand investigative toxicology, all aligned with FDA's New Approach Methodology (NAM) framework to provide human-relevant safety data for pharmaceutical and biotech drug development pipelines.
Is VivoSim Labs a public or private company?
VivoSim Labs is a public company. It is classified as public and is currently operating.
When was VivoSim Labs founded?
VivoSim Labs was founded in 2007. It employs 11 to 50 people.
Where is VivoSim Labs based?
VivoSim Labs is headquartered in San Diego, United States, in the North America region.
How does VivoSim Labs make money?
One revenue line is on record: toxicology Testing Services.
Who are VivoSim Labs's main competitors?
Emerging players on record are Emulate and TissUse. Broad incumbents are Labcorp Drug Development (formerly Covance), Inotiv, BioIVT and Charles River Laboratories. Direct peers are MIMETAS, InSphero, Cyprotex (an Evotec company) and CN Bio.
Does VivoSim Labs have an API?
No public API is recorded for VivoSim Labs.
What industry is VivoSim Labs in?
VivoSim Labs's product category is Preclinical Toxicology Testing Services. Its primary akta.pro industry code is HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip). Its NAICS code is 541714 and its SIC code is 8071.